Crinetics Pharmaceuticals prices $500M equity at $50 per share [Seeking Alpha]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Gross proceeds are expected to be $500M. Underwriters have a 30-day option to purchase up to an additional 1.5M shares. The offering is expected to close on or about October 10, 2024. Net proceeds together with its existing cash, cash equivalents and investment securities, will be used to fund research and development of its clinical-stage product candidates, other research programs, pre-commercialization activities and other general corporate purposes, which may include, among other things, capital expenditures or working capital. More on Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript Crinetics Pharmaceuticals Q2 2024 Earnings Preview Seeking Alpha's Quant Rating on Crinetics Pharmaceuticals Historical earnings data for Crinetics Pharmaceuticals Recommended For You Comments More Trending News Recommended
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024GlobeNewswire
- Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockGlobeNewswire
- Crinetics Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswire
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $80.00 price target on the stock.MarketBeat
CRNX
Earnings
- 8/8/24 - Miss
CRNX
Sec Filings
- 10/17/24 - Form SC
- 10/16/24 - Form 8-K
- 10/9/24 - Form 8-K
- CRNX's page on the SEC website